- Diabetes Research
- Glucose Meters
- Adult Onset Diabetes
- Diabetes and Exercise
- Diabetes and Insurance
- Diabetes and Sex
- Diabetes Care
- Diabetes Control
- Diabetes Cure
- Diabetes Prevention
- Diabetes Technology
- Insulin Resistance
- Type 1 Diabetes
- Type 2 Diabetes
- Type 3 Diabetes
- Battle Diabetes
New Study Demonstrates Diabetes Drug Effective in Weight Loss
Full results from a year long trial involving over 3,700 overweight and obese patients taking the drug liraglutide (Saxenda) show that patients receiving the drug lost more weight than those given placebo.
[For the sake of clarification: Liraglutide is a glucagon-like peptide-1 receptor. In the treatment of type 2 diabetes it is sold under the brand name Victoza. For weight loss, liraglutide has been reformulated and sold under the brand name Saxenda.]
In this study:
- Those on liraglutide lost an average of 8.4±7.3 kg (18.5 ± 16.1 lbs) of body weight.
- Those in the placebo group lost an average of 2.8±6.5 kg (6.2 ± 14.3 lbs).
- More than 63 percent of patients on the drug lost at least 5 percent of their body weight versus 27 percent of the placebo group.
- 33.1 percent of those in the treatment group lost more than 10 percent of their body weight.
- Just 10.6 percent lost more than 10 percent of their body weight in the placebo group.
- 14.4 percent of patients in the treatment group lost more than 15 percent of their body weight.
- 3.5 percent in the placebo group lost more than 15 percent of their body weight.
- However, 9.9 percent of patients in the treatment group withdrew from the study because of adverse events or side effects, compared to 3.8 percent of the placebo group.
- In addition to medication, both groups received both lifestyle interventions and counseling.
This study was led by Xavier Pi-Sunyer, MD, at Columbia University in New York City, and the team reported their findings in the 2 July 2015 issue of the New England Journal of Medicine.
"The treatment effect was similar in patients with prediabetes and those without prediabetes and was similar across body mass index categories," wrote Pi-Sunyer and colleagues.
In addition, the researchers found that there was a greater reduction in glycated hemoglobin, fasting glucose, and fasting insulin levels in the liraglutide group than in the placebo group.
The information provided on battlediabetes.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of battlediabetes.com nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.